Emendo
Business Services · North Carolina, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
727 W Hargett St Ste 101, Raleigh, North...Phone Number
+45 21193410Website
www.emendo.comRevenue
$24.4 MillionIndustry
About Emendo
Emendo Biotherapeutics, a subsidiary of AnGes, Inc., is a next generation CRISPR gene editing company leveraging dual proprietary technology platforms to enable high precision gene editing throughout the genome. Emendo's novel nuclease discovery platform broadens the targetable range of the genome while its target-specific optimization platform enables highly precise editing, including allele specific editing, while maintaining high efficiencies. The capabilities of the OMNI technology platforms, along with deep expertise in genomic medicine, protein engineering and therapeutic development, provide Emendo with a unique advantage when addressing indications within hematology, oncology, ophthalmology and other disease areas.Explore more
Emendo Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Emendo
Compare insights from companies similar to Emendo, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Emendo Tech Stack
A closer look at the technologies used by Emendo
See more technologies
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Emendo
Sign Up For FreeTo access detailed company insights
Emendo Biotherapeutics, a subsidiary of AnGes, Inc., is a next generation CRISPR gene editing company leveraging dual proprietary technology platforms to enable high precision gene editing throughout the genome. Emendo's novel nuclease discovery platform broadens the targetable range of the genome while its target-specific optimization platform ena... Read More
